Product Information
DAPTOMYCIN 500 MG VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $20.7686 per EA under NDC 63323037119. Its NADAC has been published 97 times since Apr 17, 2024.
FDA first approved this application on Apr 11, 2018. Its Orange Book therapeutic-equivalence code is AP.
Strength
500 mg/10mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323037119
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
2/11/2026
Active Ingredients
DAPTOMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA206077FDA Approved
4/11/2018
TE Code
AP
On Market Since
4/11/2018
Pharmacological Classes
Price Statistics
The NADAC for DAPTOMYCIN 500 MG VIAL has been published 97 times since Apr 17, 2024, and over the history we have for it it has declined 16.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.7686 per EA |
|---|---|
| All-time high | $28.3900 (Sep 11, 2024) |
| All-time low | $20.1020 (Oct 22, 2025) |
| 52-week high | $24.2743 |
| 52-week low | $20.1020 |
| Median price | $23.4554 |
| Average price | $23.1435 |
| Largest weekly change | -17.2% (Oct 22, 2025) |
| Weeks tracked | 97 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-14.4%
3Y
N/A
5Y
N/A
All
-16.4%
Last surveyed Feb 18, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Daptomycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lipopeptide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DAPTOMYCIN 500 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for DAPTOMYCIN 500 MG VIAL, manufactured by Fresenius Kabi USA, LLC, is $20.7686 per EA (NDC 63323037119), effective Feb 18, 2026.
How has the price of DAPTOMYCIN 500 MG VIAL changed over time?
Over the history we have for it, the NADAC for DAPTOMYCIN 500 MG VIAL has declined 16.4%. It has been tracked across 97 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DAPTOMYCIN 500 MG VIAL?
Since Apr 17, 2024, the NADAC for DAPTOMYCIN 500 MG VIAL has ranged from a low of $20.1020 (Oct 22, 2025) to a high of $28.3900 (Sep 11, 2024), with a median of $23.4554 per EA.
Are there cheaper alternatives to DAPTOMYCIN 500 MG VIAL?
12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DAPTOMYCIN 500 MG VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures DAPTOMYCIN 500 MG VIAL?
DAPTOMYCIN 500 MG VIAL (NDC 63323037119) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.